Simvastatin was shown to suppress phosphorylation of JAK2 and STAT3 in two human renal cell carcinoma cell lines in a nude mouse model [46] and growth hormone-stimulated JAK2 and STAT5 activation in osteosarcoma cells [47]. Here, JAK2 is linked to hereditary clear cell renal cell carcinoma.